Literature DB >> 843423

Fate of [14C]-bumetanide in man.

P J Pentikäinen, A Penttilä, P J Neuvonen, G Gothoni.   

Abstract

1. The fate of bumetanide was studied in four healthy volunteers both after intravenous oral administration of [14C]-bumetanide (0.5 mg). 2. The absorption of oral [14C]-bumetanide was rapid (absorption half-life 0.61 h) and complete with a urinary recovery of about 80% of the intravenous or oral dose during 48 h. 3. The elimination of [14C]-bumetanide was rapid with a half-life of elimination (T 1/2 beta) of 1.5 h. 4. Protein bound fraction of [14C]-bumetanide in plasma was 95%. No bumetanide was found in red blood cells. 5. Four metabolites of [14C]-bumetanide were found in urine. Together they accounted for about one third of the radio-activity excreted into urine during the first 6 h after the administration of the drug. 6. Bumetanide is rapidly and completely absorbed from the gastrointestinal tract, bound extensively to plasma proteins, metabolized to some extent and excreted rapidly, principally into urine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843423      PMCID: PMC1428996          DOI: 10.1111/j.1365-2125.1977.tb00664.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Evidence for the metabolism of bumetanide in man.

Authors:  S C Halladay; D E Carter; I G Sipes; B B Brodie; R Bressler
Journal:  Life Sci       Date:  1975-09-15       Impact factor: 5.037

2.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.

Authors:  D L Davies; A F Lant; N R Millard; A J Smith; J W Ward; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

3.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

4.  The influence of protein binding on the excretion of some sulphanilamidopyrimidines in man.

Authors:  S R Walker
Journal:  J Pharm Pharmacol       Date:  1970-08       Impact factor: 3.765

5.  Proceedings: Species differences in the diuretic activity and metabolism of bumetanide.

Authors:  M P Magnussen; E Eilertsen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

7.  GLC determination and urinary recovery of bumetanide in healthy volunteers.

Authors:  P W Feit; K Roholt; H Sorensen
Journal:  J Pharm Sci       Date:  1973-03       Impact factor: 3.534

8.  Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic.

Authors:  E H Ostergaard; M P Magnussen; C K Nielsen; E Eilertsen; H H Frey
Journal:  Arzneimittelforschung       Date:  1972-01

9.  New method for calculating the intrinsic absorption rate of drugs.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

10.  Bumetanide: potent new "loop" diuretic.

Authors:  M J Asbury; P B Gatenby; S O'Sullivan; E Bourke
Journal:  Br Med J       Date:  1972-01-22
  10 in total
  12 in total

1.  Individualization of a pharmacokinetic model by fractional and nonlinear fit improvement.

Authors:  Jovan K Popović; Mihalj Poša; Kosta J Popović; Dušica J Popović; Nataša Milošević; Vesna Tepavčević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-23       Impact factor: 2.441

Review 2.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 3.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Pharmacokinetics of mefruside and two active metabolites in man.

Authors:  H L Fleuren; C P Verwey-van Wissen; J M van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

6.  Pharmacokinetics of intravenously administered bumetanide in man.

Authors:  P J Pentikäinen; P J Neuvonen; M Kekki; A Penttilä
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

7.  The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects.

Authors:  L A Marcantonio; W H Auld; G G Skellern; C A Howes; W R Murdoch; R Purohit
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

8.  Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Authors:  Gabriele Deidda; Martina Parrini; Shovan Naskar; Ignacio F Bozarth; Andrea Contestabile; Laura Cancedda
Journal:  Nat Med       Date:  2015-03-16       Impact factor: 53.440

9.  Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee; N D Kim
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

10.  Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment.

Authors:  M R Howlett; G G Skellern; W H Auld; W R Murdoch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.